Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28373 | 0.89 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1 | |
| SCHEMBL29140614 | 0.87 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1 | |
| SCHEMBL28197279 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| SCHEMBL26694771 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| SCHEMBL28197244 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| SCHEMBL28196571 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| SCHEMBL2351582 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| Fluoride SCHEMBL11077600 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| SCHEMBL28196569 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1 | |
| Acetonitrile SCHEMBL27731948 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2389377-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8038731-B2 | hair dyes contains naphthylimide thiol or disulphide groups; resistant and visible lightening effect on dark keratin fibres; cosmetics | L'OREAL S.A. (FR) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-6329027-B1 | Chlorobenzene derivatives, liquid-crystal composition, and liquid-crystal display elements | CHISSO CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-0959060-A1 | CHLOROBENZENE DERIVATIVES, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENTS | CHISSO CORPORATION (JP) | 1999-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | ALDH1A1 2144/4885L3MBTL1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.